My watch list  

89 Current news of Abbott


You can refine your search further. Select from the filter options on the left to narrow down your results.

Abbott Receives FDA Emergency Use Authorization and Launches Test to Detect Novel Coronavirus

Company scaling up production at its U.S. manufacturing location


Abbott announced that the U.S. Food and Drug Administration has issued Emergency Use Authorization (EUA) for the company's molecular test for novel coronavirus (COVID-19). Abbott is immediately shipping 150,000 Abbott RealTime SARS-CoV-2 EUA tests to existing customers in the U.S. The tests are ...


Abbott Is Named Global Industry Leader in Sustainability for the Sixth Consecutive Year on the Dow Jones Sustainability Index (DJSI)


For the sixth consecutive year, Abbott has been named the leading company in its industry by the Dow Jones Sustainability Index (DJSI). Abbott is one of the 60 companies recognized for leading their respective global industries. The DJSI designation recognizes companies for responsible and ...


Abbott acquisition of St. Jude Medical set to close


Abbott announced it intends to close the acquisition of St. Jude Medical, Inc. The announcement follows receipt of all regulatory clearances necessary for closing. The transaction establishes Abbott as a leader in the medical device arena and provides expanded opportunities for future growth. The ...


Abbott to sell Abbott Medical Optics to Johnson & Johnson for $4.325 billion


Abbott announced that it will sell Abbott Medical Optics, its vision care business, to Johnson & Johnson for $4.325 billion in cash. "We've been actively and strategically shaping our portfolio, which has recently focused on developing leadership positions in cardiovascular devices and expanding ...


Abbott announces results of its naturally dissolving stent

First Trial in Japan Meets Primary Endpoint


Abbott announced positive one-year clinical results from ABSORB Japan, a multi-center, randomized trial comparing the safety and effectiveness of Abbott's fully dissolving Absorb™ heart stent to XIENCE ®, Abbott's market-leading, permanent drug eluting stent. The trial was conducted in 38 sites ...


Abbott Completes Acquisition of Veropharm


Abbott announced that it has acquired control of Veropharm, a Russian pharmaceutical manufacturer.Abbott has had a presence in Russia for nearly 40 years and, in line with its long-term commitment to growing global healthcare markets and capabilities, the company is committed to providing a ...


Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan

Abbott will retain its branded generics pharmaceuticals business in emerging markets


Abbott announced that it will sell its developed markets branded generics pharmaceuticals business to Mylan for equity ownership of a newly formed entity that will combine Mylan's existing business and Abbott's developed markets pharmaceuticals business, and will be a publicly traded company. ...


Abbott to Acquire Veropharm


Abbott announced a definitive agreement to acquire Veropharm, a Russian pharmaceutical manufacturer. Under the terms of the agreement, Abbott will acquire Limited Liability Company Garden Hills, the holding company that currently owns a controlling interest in Veropharm, for between 13.6 billion ...


Abbott acquires CFR Pharmaceuticals

Abbott doubles its Latin American branded generics pharmaceutical presence


Abbott announced a definitive agreement to acquire Latin American pharmaceutical company CFR Pharmaceuticals, more than doubling its Latin American branded generics pharmaceutical presence and further expanding Abbott's presence in fast-growing markets. Under the terms of the agreement, Abbott ...


Abbott completes separation of research-based pharmaceuticals business


Abbott announced it has completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. AbbVie begins trading independently on the New York Stock Exchange under the symbol "ABBV." "We wish our colleagues at AbbVie ...


Page 1 From 9
Subscribe to e-mail updates relating to your search

You will receive via e-mail the latest search results matching your search criteria. This service is free of charge and can be cancelled at any time.

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE